'''Rolipram''' is a selective [[phosphodiesterase-4 inhibitor]] discovered and developed by [[Schering AG]] as a potential [[antidepressant]] drug in the early 1990s.<ref name="Zhu 387–98">{{cite journal|last=Zhu|first=J|author2=Mix, E |author3=Winblad, B |title=The antidepressant and antiinflammatory effects of rolipram in the central nervous system.|journal=CNS Drug Reviews|date=Winter 2001|volume=7|issue=4|pages=387–98|pmid=11830756|doi=10.1111/j.1527-3458.2001.tb00206.x}}</ref>  It served as a prototype molecule for several companies' [[drug discovery]] and development efforts.<ref name=McKenna>McKenna, JM and Muller, GW.  Medicinal Chemistry of PDE4 Inhibitors. Chapter 33 in Cyclic Nucleotide Phosphodiesterases in Health and Disease, Eds Joseph A. Beavo et al. CRC Press, Dec 5, 2006 {{ISBN|9781420020847}}</ref>{{rp|668ff}}  Rolipram was discontinued after clinical trials showed that its [[therapeutic window]] was too narrow; it could not be dosed at high enough levels to be effective without causing significant gastrointestinal side effects.<ref name=McKenna/>{{rp|668}}
